Table 4.
Comparison of serum biomarker concentrations in HALT-A (eGFR >60 ml·min−1·1.73 m−2, n = 61) and HALT-B (eGFR 25-60 ml·min−1·1.73 m−2, n = 49) patients
| Variable | HALT-A (eGFR >60 ml·min−1·1.73 m−2) | HALT-B (eGFR <60 ml·min−1·1.73 m−2) | P Value |
|---|---|---|---|
| NO pathway and endothelial dysfunction markers | |||
| ADMA, μM | 0.89 ± 0.19 | 0.92 ± 0.16 | 0.3821 |
| Arginine, μM | 81.9 ± 27.6 | 94.7 ± 35.0 | 0.0323 |
| Cysteine μM | 200.7 ± 64.5 | 209.8 ± 34.3 | 0.3708 |
| Homocysteine, μM | 12.7 ± 4.1 | 16.4 ± 2.0 | <0.0001 |
| Methionine, μM | 21.6 ± 7.1 | 48.7 ± 16.5 | <0.0001 |
| SAH, nM | 182.6 ± 39.1 | 604.9 ± 90.5 | <0.0001 |
| SAM, nM | 382.0 ± 122.4 | 367.0 ± 135.4 | 0.5487 |
| SAM/SAH | 2.18 ± 0.77 | 0.20 ± 0.07 | <0.0001 |
| SDMA, μM | 1.86 ± 0.89 | 1.97 ± 0.62 | 0.4534 |
| Oxidative stress and inflammation markers | |||
| Glutathione, μM | 4.17 ± 3.09 | 5.28 ± 2.08 | 0.0317 |
| PGD2, pg/ml | 663.2 ± 501.7 | 4,510.4 ± 3,482.6 | <0.0001 |
| PGE2, pg/ml | 675.9 ± 377.1 | 1,242.4 ± 1,095.8 | 0.0006 |
| PGF2α, pg/ml | 160.9 ± 94.6 | 530.0 ± 424.4 | <0.0001 |
| 8-Isoprostane, pg/ml | 90.8 ± 55.6 | 185.7 ± 203.2 | 0.0015 |
Data are presented as mean ± SD. P value <0.05 was considered significant and is marked in bold.